Methimazole Induced Total Myeloid Aplasia with Delayed Recovery Despite Granulocyte Colony Stimulating Factor (G-CSF): Marrow Progenitor Recovery Kinetics

Sarker, Tania; Özgönenel, Bülent; Gadgeel, Manisha; Buck, Steven; Adhikari, Amita; Ravindranath, Yaddanapudi

doi:10.1007/s12288-015-0595-1

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, decitabine assisted in the treatment of MDS by regulating the production of ROS (Wang, Guo, Guo, Zhang, & Ren, 2019a). It has been found that methimazole can interfere with the oxidation of tyrosine groups by inhibiting peroxidase, leading to anemia or granulocyte deficiency, and myeloid aplasia (Sarker et al, 2015; Yang et al, 2013). Methimazole increased dramatically in the MDS group, indicating that methimazole metabolism was affected, and HSCT had a regulatory effect on methylimidazole.…”

Section: Discussionmentioning

confidence: 99%

Integrative metabolic profile of myelodysplastic syndrome based on UHPLC–MS

Yuan

Zhao

et al. 2021

Biomedical Chromatography

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) is a neoplastic disease originating from hematopoietic stem cells. Currently, hematopoietic stem cell transplantation (HSCT) is the most effective cure, although lenalidomide, azacytidine, and decitabine have been applied to relieve symptoms of MDS. The purpose of this study was to evaluate the changes in endogenous metabolites by applying a UHPLC–MS (ultra–high‐performance liquid chromatography–MS) metabolomics approach and to investigate metabolic pathways related to MDS. An untargeted metabolomics approach based on UHPLC–MS in combination with multivariate data analysis, including partial least squares discrimination analysis and orthogonal partial least squares discriminant analysis, was established to investigate potential biomarkers in the plasma of MDS patients. As a result, 29 biomarkers were identified to distinguish between MDS patients, HSCT patients, and healthy controls, which were mainly related to inflammation regulation, amino acid metabolism, fatty acid metabolism, and energy metabolism. To our knowledge, this is the first time where plasma metabolomics was combined with HSCT to study the pathogenesis and therapeutic target of MDS. The identification of biomarkers and analysis of metabolic pathways could offer the possibility of discovering new therapeutic targets for MDS in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrative metabolic profile of myelodysplastic syndrome based on UHPLC–MS

Yuan

Zhao

et al. 2021

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…Bone marrow examination showed that the M:E ratio was <0.5. Hence, bone marrow recovery from agranulocytosis after G-CSF treatment was delayed (40). Furthermore, the older the patients, the less active the bone marrow.…”

Section: Discussionmentioning

confidence: 99%

Granulocyte-Colony-Stimulating Factor Effectively Shortens Recovery Duration in Anti-Thyroid-Drug-Induced Agranulocytosis: A Systematic Review and Meta-Analysis

Wang

Yang

et al. 2019

Front. Endocrinol.

View full text Add to dashboard Cite

Background and aim: Granulocyte-colony-stimulating factor (G-CSF) is highly beneficial as a general treatment for anti-thyroid drug (ATD)-induced agranulocytosis. This meta-analysis aimed to assess the clinical effects of G-CSF and non-G-CSF on recovery duration in patients with ATD-induced agranulocytosis by analyzing the overall clinical outcomes.Methods: The PubMed, Embase, Ovid, Cochrane, Google Scholar, China National Knowledge Infrastructure (CNKI) databases were searched for published studies from 1900 to 2018. No language restriction was implemented.Results: This meta-analysis included 10 published retrospective studies and one prospective study. Data were obtained from 11 trials (474 patients: 247 with G-CSF and 227 with non-G-CSF treatment). Compared with the non-G-CSF group, the G-CSF group presented shorter recovery duration [weighted mean difference (WMD) = −3.04 days, 95% confidence interval (95% CI): −4.38 to −1.69 (Z = 4.43 P = 0.000)]. However, the recovery duration varied across regions and recovery criteria. Asian patients achieved significant clinical outcomes [WMD = −3.16 days (95% CI: −4.58 to −1.74, P = 0.000)] compared with European and South American patients [WMD = −2.19 days (95% CI: −7.38 to 3.01, P = 0.409)]. Also, according to various recovery criteria, a duration of granulocyte count increase of more than 1.5 or 1.0 × 109/L [WMD = −3.50 days (95% CI: −4.82 to −2.18, P = 0.000)] revealed a better treatment effect.Conclusion: G-CSF can significantly shorten the recovery duration in patients with ATD-induced agranulocytosis.

show abstract

Thiamazole

2016

Reactions Weekly

View full text Add to dashboard Cite

Methimazole Induced Total Myeloid Aplasia with Delayed Recovery Despite Granulocyte Colony Stimulating Factor (G-CSF): Marrow Progenitor Recovery Kinetics

Cited by 4 publications

References 24 publications

Integrative metabolic profile of myelodysplastic syndrome based on UHPLC–MS

Integrative metabolic profile of myelodysplastic syndrome based on UHPLC–MS

Granulocyte-Colony-Stimulating Factor Effectively Shortens Recovery Duration in Anti-Thyroid-Drug-Induced Agranulocytosis: A Systematic Review and Meta-Analysis

Thiamazole

Contact Info

Product

Resources

About